Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 5:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 3,317 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pancreatic Diseases Clear all
Completed Phase 2 Interventional Results available

Effects of an Antioxidant-Enriched Multivitamin Supplement on Inflammation and Oxidative Stress in Cystic Fibrosis

NCT01859390
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
AquADEKs-2, control multivitamin
Drug · Dietary Supplement
Lead sponsor
University of Colorado, Denver
Other
Eligibility
10 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
15
States / cities
Tucson, Arizona • Aurora, Colorado • Orlando, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2017 · Synced Oct 3, 2026, 5:32 PM EDT
Recruiting Phase 1Phase 2 Interventional

Intratumoral MMR Vaccine Injection in Borderline Resectable/Unresectable Pancreatic Cancer

NCT07539155
View directory record Official record
Conditions
Borderline Resectable/Unresectable Pancreatic Cancer, Non Metastatic Pancreatic Cancer
Interventions
Intratumoral MMR Injection
Biological
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 3, 2026, 5:32 PM EDT
Completed Not applicable Interventional Results available

Feasibility of a Decision Support System to Reduce Glucose Variability in Subject With T1DM

NCT02558491
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Decision Support System, Usual Care
Device · Other
Lead sponsor
Daniel Chernavvsky, MD
Other
Eligibility
21 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 7, 2024 · Synced Oct 3, 2026, 5:32 PM EDT
Not yet recruiting Phase 1 Interventional

Phase I Open-Label Randomized Multicenter Study of XNW28012 Monotherapy in Metastatic Pancreatic Cancer

NCT07707674
View directory record Official record
Conditions
Metastatic Pancreatic Cancer
Interventions
XNW28012
Drug
Lead sponsor
Evopoint Biosciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
8
States / cities
Detroit, Michigan • Grand Rapids, Michigan • Lake Success, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 3, 2026, 5:32 PM EDT
Completed Phase 2 Interventional Results available

Genistein, Gemcitabine, and Erlotinib in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

NCT00376948
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
genistein, erlotinib hydrochloride, gemcitabine hydrochloride
Dietary Supplement · Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
21 Years to 120 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
2
States / cities
Detroit, Michigan • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 1, 2021 · Synced Oct 3, 2026, 5:32 PM EDT
Completed Not applicable Interventional

Outpatient Control-to-Range: System and Monitoring Testing

NCT01697150
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
DiAs Diabetes Assistant Wearable Artificial Pancreas Platform
Device
Lead sponsor
Sansum Diabetes Research Institute
Other
Eligibility
21 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Apr 21, 2016 · Synced Oct 3, 2026, 5:32 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study of FOLFIRINOX (mFFX) +/- SBRT in Locally Advanced Pancreatic Cancer

NCT01926197
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Oxaliplatin, Irinotecan, Leucovorin, 5FU, Stereotactic Body Radiotherapy (SBRT)
Drug · Radiation
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2022 · Synced Oct 3, 2026, 5:32 PM EDT
Recruiting Phase 2 Interventional

Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis

NCT06747858
View directory record Official record
Conditions
Cystic Fibrosis, CFTR Gene Mutation
Interventions
ARCT-032
Biological
Lead sponsor
Arcturus Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
13
States / cities
Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 3, 2026, 5:32 PM EDT
Terminated Phase 1 Interventional Results available

Pemetrexed, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer

NCT00310050
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
pemetrexed disodium, Radiotherapy
Drug · Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 30, 2018 · Synced Oct 3, 2026, 5:32 PM EDT
Terminated Not applicable Interventional

EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer

NCT00087191
View directory record Official record
Conditions
Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Fallopian Tube Cancer, Gastrointestinal Stromal Tumor, Localized Extrahepatic Bile Duct Cancer, Localized Gallbladder Cancer, Localized Gastrointestinal Carcinoid Tumor, Localized Resectable Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Metastatic Gastrointestinal Carcinoid Tumor, Ovarian Sarcoma, Ovarian Stromal Cancer, Primary Peritoneal Cavity Cancer, Recurrent Adult Primary Liver Cancer, Recurrent Adult Soft Tissue Sarcoma, Recurrent Colon Cancer, Recurrent Extrahepatic Bile Duct Cancer, Recurrent Gallbladder Cancer, Recurrent Gastric Cancer, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Pancreatic Cancer, Recurrent Rectal Cancer, Recurrent Small Intestine Cancer, Recurrent Uterine Sarcoma, Regional Gastrointestinal Carcinoid Tumor, Small Intestine Adenocarcinoma, Small Intestine Leiomyosarcoma, Small Intestine Lymphoma, Stage 0 Non-small Cell Lung Cancer, Stage I Adult Soft Tissue Sarcoma, Stage I Colon Cancer, Stage I Gastric Cancer, Stage I Non-small Cell Lung Cancer, Stage I Ovarian Epithelial Cancer, Stage I Ovarian Germ Cell Tumor, Stage I Pancreatic Cancer, Stage I Rectal Cancer, Stage I Uterine Sarcoma, Stage II Adult Soft Tissue Sarcoma, Stage II Colon Cancer, Stage II Gastric Cancer, Stage II Non-small Cell Lung Cancer, Stage II Ovarian Epithelial Cancer, Stage II Ovarian Germ Cell Tumor, Stage II Pancreatic Cancer, Stage II Rectal Cancer, Stage II Uterine Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage III Colon Cancer, Stage III Gastric Cancer, Stage III Ovarian Epithelial Cancer, Stage III Ovarian Germ Cell Tumor, Stage III Pancreatic Cancer, Stage III Rectal Cancer, Stage III Uterine Sarcoma, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Adult Soft Tissue Sarcoma, Stage IV Colon Cancer, Stage IV Gastric Cancer, Stage IV Non-small Cell Lung Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor, Stage IV Pancreatic Cancer, Stage IV Rectal Cancer, Stage IV Uterine Sarcoma, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer
Interventions
EF5, motexafin lutetium, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 16, 2013 · Synced Oct 3, 2026, 5:32 PM EDT
Completed Phase 1 Interventional

Study of XB002 in Subjects With Solid Tumors (JEWEL-101)

NCT04925284
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Cervical Cancer, SCCHN, Pancreatic Cancer, Esophageal SCC, Metastatic Castration-resistant Prostate Cancer, Triple Negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Epithelial Ovarian Cancer, Endometrial Cancer, Tissue Factor-Expressing Solid Tumors
Interventions
XB002, Nivolumab, Bevacizumab
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
34
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 3, 2026, 5:32 PM EDT
Not listed Phase 1Phase 2 Interventional

A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies

NCT03607643
View directory record Official record
Conditions
Cancer of Pancreas, Cancer of Liver, Cancer of Rectum, Cancer of Colon, Cancer, Gall Bladder, Myeloma Multiple, Glioblastoma Multiforme
Interventions
Cannabidiol, Bortezomib, Leucovorin, 5-FU, Oxaliplatin, Bevacizumab, Irinotecan, Gemcitabine, Temozolomide
Drug
Lead sponsor
Leaf Vertical Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Oct 3, 2026, 5:32 PM EDT
Completed Phase 1Phase 2 Interventional

A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors

NCT03997968
View directory record Official record
Conditions
Malignancy, Non-hodgkin Lymphoma, Multiple Myeloma, Breast Cancer, Ovarian Cancer, Soft Tissue Sarcoma, Head and Neck Cancer, DLBCL, Mantle Cell Lymphoma, Follicular Lymphoma, Pancreatic Cancer, CLL, Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer
Interventions
CYT-0851, CYT-0851 in combination with gemcitabine, CYT-0851 in combination with capecitabine, CYT-0851 in combination with rituximab and bendamustine
Drug
Lead sponsor
Cyteir Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
16
States / cities
San Francisco, California • Stanford, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2024 · Synced Oct 3, 2026, 5:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Study of Lansoprazole in Cystic Fibrosis

NCT00458614
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Lansoprazole
Drug
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
2 Years to 10 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jan 11, 2011 · Synced Oct 3, 2026, 5:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Detection of Pseudomonas Aeruginosa in the Airways of Patients With CF

NCT01303068
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
13C urea breath test Kit
Device
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Oct 3, 2026, 5:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The BurnAlong Pilot Study for Adolescent and Young Adult Cancer Survivors

NCT05131815
View directory record Official record
Conditions
Cancer, Cancer Metastatic, Neoplasms, Breast Cancer, Lung Cancer, Thyroid Cancer, Lymphoma, Lymphoma, Non-Hodgkin, Hodgkin Lymphoma, Leukemia, Sarcoma, Skin Cancer, Bone Cancer, Gynecologic Cancer, Pancreas Cancer, Multiple Myeloma, Colorectal Cancer, Gastrointestinal Cancer, Prostate Cancer, Glioblastoma, Brain Cancer, Head and Neck Cancer
Interventions
Virtual group based physical activity (BurnAlong) and Social Media Discussion Board
Behavioral
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 39 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 26, 2025 · Synced Oct 3, 2026, 5:32 PM EDT
Completed Phase 3 Interventional

A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas.

NCT00035035
View directory record Official record
Conditions
Pancreatic Neoplasms, Metastases, Neoplasm
Interventions
GEMZAR, ALIMTA
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
40
States / cities
Huntsville, Alabama • Fountain Valley, California • Fullerton, California + 37 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2006 · Synced Oct 3, 2026, 5:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Multilevel Models of Therapeutic Response in the Lungs

NCT02947126
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Hypertonic Saline, Isotonic Saline, Indium-DTPA, Technetium Sulfur Colloid
Drug
Lead sponsor
Tim Corcoran
Other
Eligibility
12 Years and older
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 13, 2023 · Synced Oct 3, 2026, 5:32 PM EDT
Completed Phase 2 Interventional

A Study With LY293111, Gemcitabine and Placebo in Patients With Pancreatic Cancer

NCT00055250
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Gemcitabine, LY293111, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Lakeland, Florida
Source: ClinicalTrials.gov public record
Updated Jan 26, 2007 · Synced Oct 3, 2026, 5:32 PM EDT
Recruiting Not applicable Interventional

FEED-Cystic Fibrosis (FEED-CF)

NCT05766774
View directory record Official record
Conditions
Cystic Fibrosis, Cystic Fibrosis-related Diabetes
Interventions
Low-added sugar, high-fat diet, High-added sugar, high-fat CF diet
Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 3, 2026, 5:32 PM EDT
Not listed No phase listed Observational

PRedictiOn Algorithms for the DeTECTion of Early Stage Pancreatic Cancer

NCT04883450
View directory record Official record
Conditions
Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma (PDAC)
Interventions
Magnetic resonance imaging (MRI)
Diagnostic Test
Lead sponsor
Kaiser Permanente
Other
Eligibility
50 Years to 84 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Jan 16, 2024 · Synced Oct 3, 2026, 5:32 PM EDT
Completed Phase 1 Interventional Results available

A Pharmacokinetic and Safety Study of IV Gallium Nitrate (Ganite) in Cystic Fibrosis Patients

NCT01093521
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
100 mg/m2 dose, 200 mg/m2 dose
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
3
States / cities
Iowa City, Iowa • Baltimore, Maryland • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 29, 2022 · Synced Oct 3, 2026, 5:32 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Role of a CCK Receptor Antagonist Proglumide in Management of Chronic Pancreatitis

NCT05551858
View directory record Official record
Conditions
Safety Issues, Pain, Pancreas Fibrosis
Interventions
Proglumide, Placebo
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 3, 2026, 5:32 PM EDT
Completed Phase 1Phase 2 Interventional

Combination With Gemcitabine in Advanced Pancreatic Cancer

NCT01251640
View directory record Official record
Conditions
Pancreatic Neoplasms
Interventions
BAY86-9766+Gemcitabine
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 99 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Aurora, Colorado • Pittsfield, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Oct 3, 2026, 5:32 PM EDT